These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32585057)

  • 1. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
    Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
    Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
    Novosad J; Krčmová I
    Int J Immunopathol Pharmacol; 2020; 34():2058738420942386. PubMed ID: 32689848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
    Samitas K; Delimpoura V; Zervas E; Gaga M
    Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
    Evans MO; Morris MJ; Coop CA; Evans SE
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
    [No Abstract]   [Full Text] [Related]  

  • 7. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
    Lieberman PL; Umetsu DT; Carrigan GJ; Rahmaoui A
    J Allergy Clin Immunol; 2016 Sep; 138(3):913-915.e2. PubMed ID: 27236498
    [No Abstract]   [Full Text] [Related]  

  • 8. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
    Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xolair in asthma therapy: an overview.
    Di Domenico M; Bisogno A; Polverino M; De Rosa C; Ricci V; Capasso A
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):2-12. PubMed ID: 21184647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma.
    Frix AN; Schleich F; Paulus V; Guissard F; Henket M; Louis R
    Biochem Pharmacol; 2020 Sep; 179():113944. PubMed ID: 32240649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.
    Pelaia C; Calabrese C; Terracciano R; de Blasio F; Vatrella A; Pelaia G
    Ther Adv Respir Dis; 2018; 12():1753466618810192. PubMed ID: 30400762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole blood transcriptional variations between responders and non-responders in asthma patients receiving omalizumab.
    Upchurch K; Wiest M; Cardenas J; Skinner J; Nattami D; Lanier B; Millard M; Joo H; Turner J; Oh S
    Clin Exp Allergy; 2020 Sep; 50(9):1017-1034. PubMed ID: 32472607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.